However, the ‘classical’ chemotherapy, including anthracyclines and human epidermal growth factor receptor 2 antagonists (HER2) in case of HER2 positive expression, are still the pillars of breast cancer therapy with a risk for acute and long-term cardiovascular toxicity. This evidence concerns the gene ERBB2 and breast carcinoma.